chemical

aTAG 2139

6970

5 mg

373 USD

6970

6970/5

aTAG 2139

Degrader of MTH1 fusion proteins for use within the aTAG system

TAG Degradation Platforms

Small Molecules

5 mg

98%

782.81

?utm_source=distributor&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules

Degrader of MTH1 fusion proteins for use within the aTAG system. Comprises a ligand selective for MTH1, a linker and the cereblon-binding ligand Thalidomide (Cat. No. 0652). Induces highly potent and selective degradation of fusion proteins after a 4 h incubation (DC50 = 0.27 nM; Dmax = 92.1%). Cell-permeable. Suitable for in vitro and in vivo applications. . Mouse DMPK properties are provided in the supplementary file (see below). . MTH1 can be expressed as a fusion with a target protein of interest using genome engineering techniques via CRISPR-mediated locus-specific knock-in. See protocol for more information. . Custom knock-in cell lines for the dTAG and aTAG platforms are available from our sister brand R&D Systems . Email TPD@bio-techne.com to enquire.

6970

aTAG2139 CFT2139 atag Achilles heel degraders degradation MTH1 fusion protein PROTAC proteolysis targeting chimeras targeted TPD CFT 2139 TAG Degradation Platform 6970,

Degrader of MTH1 fusion proteins for use within the aTAG system

6-(6-((4-(2-((2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)carbamoyl)pyridin-3-yl)-N-methyl-4-(phenylamino)quinoline-3-carboxamide

C 42 H 38 N 8 O 8

C42H38N8O8

2387510-81-6

355

373 USD

CFT 2139

Store at -20°C